Cargando…

Symptom Relief Following a Single Dose of Propylene Glycol-Hydroxypropyl Guar Nanoemulsion in Patients with Dry Eye Disease: A Phase IV, Multicenter Trial

PURPOSE: To evaluate symptom relief in patients with dry eye disease (DED) following a single drop of propylene glycol-hydroxypropyl guar (PG-HPG) nanoemulsion (Systane(®) Complete) lubricant eye drops. METHODS: This was a Phase IV, multicenter, open-label, interventional study in adult patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Silverstein, Steven, Yeu, Elizabeth, Tauber, Joseph, Guillon, Michel, Jones, Lyndon, Galarreta, David, Srinivasan, Sruthi, Manoj, Venkiteshwar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555274/
https://www.ncbi.nlm.nih.gov/pubmed/33116367
http://dx.doi.org/10.2147/OPTH.S263362
Descripción
Sumario:PURPOSE: To evaluate symptom relief in patients with dry eye disease (DED) following a single drop of propylene glycol-hydroxypropyl guar (PG-HPG) nanoemulsion (Systane(®) Complete) lubricant eye drops. METHODS: This was a Phase IV, multicenter, open-label, interventional study in adult patients with DED of aqueous-deficient, evaporative, and mixed subtypes. Patients instilled one drop of PG-HPG in each eye at Day 1. Endpoints included change from baseline in dry eye symptom and soothing sensation scores on Day 1 at 0, 4, and 8 hours post-dose. Symptom scores were assessed on a 0–10 scale (0=no symptoms; 10=worst imaginable symptom). Tolerability of the drop was assessed based on assessment score on Day 1 following instillation for overall cohort and by DED subtype. RESULTS: A total of 134 patients received treatment (mean age: 56.6 years; female: 75.4%). Median changes from baseline at Day 1 in dry eye symptom scores were −1.0 (95% confidence interval [CI]:-3.0,-1.0), −2.0 (95% CI:-3.0,-2.0), and −2.0 (95% CI:-2.0,-1.0) at 0, 4, and 8 hours respectively. Subgroup analysis showed a median change from baseline in dry eye symptom score of −2 (95% CI:-3.0,-1.0) for aqueous-deficient and evaporative subtypes and −1 (95% CI:-3.0,-1.0) for mixed subtype at 8 hours. Median soothing sensation scores were 3 at 0 and 4 hours and 3.5 at 8 hours, with a range of 0–10. Median (range) tolerability assessment scores were 0 (0–8) for burning sensation, stinging sensation, blurring, and 0 (0–10) for foreign body sensation. Tolerability assessment scores by DED subtype confirmed that the majority of patients reported scores in the range of 0–5 for all components and in all subgroups analyzed. CONCLUSION: Our study demonstrated that PG-HPG nanoemulsion provided instant/immediate and sustained symptom relief for 8 hours post-single application and was well tolerated in patients with DED, demonstrated by their responses on each of the assessment scales.